These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21674534)

  • 21. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
    Finkel RS; Finanger E; Vandenborne K; Sweeney HL; Tennekoon G; Shieh PB; Willcocks R; Walter G; Rooney WD; Forbes SC; Triplett WT; Yum SW; Mancini M; MacDougall J; Fretzen A; Bista P; Nichols A; Donovan JM
    Neuromuscul Disord; 2021 May; 31(5):385-396. PubMed ID: 33678513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.
    Khan N; Eliopoulos H; Han L; Kinane TB; Lowes LP; Mendell JR; Gordish-Dressman H; Henricson EK; McDonald CM;
    J Neuromuscul Dis; 2019; 6(2):213-225. PubMed ID: 30856119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
    Stockschläder M; Kalhs P; Peters S; Zeller W; Krüger W; Kabisch H; Lechner K; Zander A
    Bone Marrow Transplant; 1993 Oct; 12(4):357-62. PubMed ID: 8275035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.
    Finkel RS; McDonald CM; Lee Sweeney H; Finanger E; Neil Knierbein E; Wagner KR; Mathews KD; Marks W; Statland J; Nance J; McMillan HJ; McCullagh G; Tian C; Ryan MM; O'Rourke D; Müller-Felber W; Tulinius M; Burnette WB; Nguyen CT; Vijayakumar K; Johannsen J; Phan HC; Eagle M; MacDougall J; Mancini M; Donovan JM;
    J Neuromuscul Dis; 2021; 8(5):769-784. PubMed ID: 34120912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration.
    Weber MA; Nagel AM; Wolf MB; Jurkat-Rott K; Kauczor HU; Semmler W; Lehmann-Horn F
    J Neurol; 2012 Nov; 259(11):2385-92. PubMed ID: 22544297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
    Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
    JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.
    Mok E; Letellier G; Cuisset JM; Denjean A; Gottrand F; Alberti C; Hankard R
    PLoS One; 2009; 4(5):e5448. PubMed ID: 19421321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel treatment regimen for Duchenne muscular dystrophy.
    Li M; Cai Y; Zhong M; Zou L; Gong C
    Neuroreport; 2013 Nov; 24(16):924-7. PubMed ID: 24045777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early prednisone treatment in Duchenne muscular dystrophy.
    Merlini L; Cicognani A; Malaspina E; Gennari M; Gnudi S; Talim B; Franzoni E
    Muscle Nerve; 2003 Feb; 27(2):222-7. PubMed ID: 12548530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy.
    Vry J; Schubert IJ; Semler O; Haug V; Schönau E; Kirschner J
    Eur J Paediatr Neurol; 2014 Mar; 18(2):140-9. PubMed ID: 24157400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.
    McDonald CM; Henricson EK; Abresch RT; Han JJ; Escolar DM; Florence JM; Duong T; Arrieta A; Clemens PR; Hoffman EP; Cnaan A;
    Muscle Nerve; 2013 Jul; 48(1):32-54. PubMed ID: 23677550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic modifiers of respiratory function in Duchenne muscular dystrophy.
    Bello L; D'Angelo G; Villa M; Fusto A; Vianello S; Merlo B; Sabbatini D; Barp A; Gandossini S; Magri F; Comi GP; Pedemonte M; Tacchetti P; Lanzillotta V; Trucco F; D'Amico A; Bertini E; Astrea G; Politano L; Masson R; Baranello G; Albamonte E; De Mattia E; Rao F; Sansone VA; Previtali S; Messina S; Vita GL; Berardinelli A; Mongini T; Pini A; Pane M; Mercuri E; Vianello A; Bruno C; Hoffman EP; Morgenroth L; Gordish-Dressman H; McDonald CM; ; Pegoraro E
    Ann Clin Transl Neurol; 2020 May; 7(5):786-798. PubMed ID: 32343055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous pentoxifylline is well tolerated in critically ill preterm infants with sepsis or necrotizing enterocolitis.
    Schüller SS; Kempf K; Unterasinger L; Strunk T; Berger A
    Eur J Pediatr; 2020 Aug; 179(8):1325-1330. PubMed ID: 32179980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
    Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study.
    Banerjee B; Sharma U; Balasubramanian K; Kalaivani M; Kalra V; Jagannathan NR
    Magn Reson Imaging; 2010 Jun; 28(5):698-707. PubMed ID: 20395096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy.
    Ricotti V; Spinty S; Roper H; Hughes I; Tejura B; Robinson N; Layton G; Davies K; Muntoni F; Tinsley J
    PLoS One; 2016; 11(4):e0152840. PubMed ID: 27055247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.